A

Aurinia Pharmaceuticals

AUPH

5.60000
USD
-0.28
(-4.76%)
Market Closed
Volume
18,310
EPS
0
Div Yield
0
P/E
-20
Market Cap
1,010,946,186
Related Instruments
A
ACAD
-0.020
(-0.11%)
19.000 USD
AMGN
2.78
(0.84%)
335.22 USD
BMY
0.620
(1.30%)
48.180 USD
C
CRBP
-0.500
(-0.84%)
59.160 USD
E
ESPR
-0.13000
(-5.62%)
2.18500 USD
GILD
0.470
(0.62%)
76.510 USD
I
INCY
-0.680
(-1.05%)
64.390 USD
REGN
13.14
(1.22%)
1,091.19 USD
VRTX
9.75
(1.97%)
505.40 USD
News

Title: Aurinia Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.